Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS
IBER.WS was delisted on the 15th of February, 2023.
21 hedge funds and large institutions have $3.14M invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 20 → 21 (+1)
4% less capital invested
Capital invested by funds: $3.27M → $3.14M (-$137K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
+$85.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$73.7K |
| 3 |
CAC
Cowen and Company
New York
|
+$37K |
| 4 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$35.4K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$25.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$57K |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
-$31K |
IBER.WS Hedge Fund Activity: Q3 2021 in Review
21 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q3 2021, worth a combined $3.14M — down 4.2% from $3.27M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IBER.WS positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Castle Creek Arbitrage, opening a new position worth an estimated $85.1K. The largest seller was Mangrove Partners, exiting entirely with an estimated $57K sold.
- 21 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q3 2021, up from 20 in Q2 2021.
- Funds reported $3.14M of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q3 2021, down 4.2% quarter-over-quarter.
- 3 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q3 2021 and 2 closed out, a net change of +1 holder.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share buyer in Q3 2021 was Castle Creek Arbitrage, an estimated $85.1K added.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q3 2021 was Mangrove Partners, an estimated $57K sold.
Based on aggregated 13F filings for Q3 2021.